Drug Delivery: Moving from Platform to Product

The traditional drug-delivery business model of service for hire has fallen from popularity. Big Pharmas are doing few deals of this sort, and investors want bigger returns than fees and royalties can provide. Start-ups with drug delivery technologies are increasingly using their platforms on their own behalf, to create products they can out-license or possibly market themselves. Now content--getting the molecules to be delivered--is an issue.